Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 262

1.

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers.

Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S, Jansen KU, Love J, Gruber WC, Emini EA, Scott DA; 004 Study Group.

Pediatrics. 2010 Sep;126(3):e493-505. doi: 10.1542/peds.2009-3027. Epub 2010 Aug 23.

PMID:
20732948
2.

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.

Esposito S, Tansey S, Thompson A, Razmpour A, Liang J, Jones TR, Ferrera G, Maida A, Bona G, Sabatini C, Pugni L, Emini EA, Gruber WC, Scott DA, Principi N.

Clin Vaccine Immunol. 2010 Jun;17(6):1017-26. doi: 10.1128/CVI.00062-10. Epub 2010 Apr 28.

3.

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.

Bryant KA, Block SL, Baker SA, Gruber WC, Scott DA; PCV13 Infant Study Group.

Pediatrics. 2010 May;125(5):866-75. doi: 10.1542/peds.2009-1405.

PMID:
20435707
5.

Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany.

Kieninger DM, Kueper K, Steul K, Juergens C, Ahlers N, Baker S, Jansen KU, Devlin C, Gruber WC, Emini EA, Scott DA; 006 study group.

Vaccine. 2010 Jun 7;28(25):4192-203. doi: 10.1016/j.vaccine.2010.04.008. Epub 2010 Apr 22.

PMID:
20417262
6.

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.

Vanderkooi OG, Scheifele DW, Girgenti D, Halperin SA, Patterson SD, Gruber WC, Emini EA, Scott DA, Kellner JD; Canadian PCV13 Study Group.

Pediatr Infect Dis J. 2012 Jan;31(1):72-7. doi: 10.1097/INF.0b013e318233049d.

PMID:
21960186
7.

A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil.

Weckx LY, Thompson A, Berezin EN, de Faria SM, da Cunha CA, Pride M, Patterson S, Gruber WC, Emini EA, Scott DA; 012 Study Group.

Vaccine. 2012 Dec 14;30(52):7566-72. doi: 10.1016/j.vaccine.2012.10.040. Epub 2012 Oct 22.

PMID:
23099331
8.

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines.

Kim DS, Shin SH, Lee HJ, Hong YJ, Lee SY, Choi KM, Oh CE, Kim KH, Juergens C, Patterson S, Giardina PC, Gruber WC, Emini EA, Scott DA.

Pediatr Infect Dis J. 2013 Mar;32(3):266-73. doi: 10.1097/INF.0b013e3182748bb6.

PMID:
23011012
9.

Immunogenicity, safety and tolerability of 3 lots of 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in the United States.

Payton T, Girgenti D, Frenck RW, Patterson S, Love J, Razmpour A, Sidhu MS, Emini EA, Gruber WC, Scott DA.

Pediatr Infect Dis J. 2013 Aug;32(8):871-80. doi: 10.1097/INF.0b013e3182906499.

PMID:
23584582
10.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in India.

Amdekar YK, Lalwani SK, Bavdekar A, Balasubramanian S, Chhatwal J, Bhat SR, Verghese VP, Tansey SP, Gadgil D, Jiang Q, Pride M, Emini EA, Gruber WC, Scott DA.

Pediatr Infect Dis J. 2013 May;32(5):509-16. doi: 10.1097/INF.0b013e31827b478d.

PMID:
23190777
11.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants.

Grimprel E, Laudat F, Patterson S, Baker SA, Sidhu MS, Gruber WC, Emini EA, Scott DA.

Vaccine. 2011 Dec 6;29(52):9675-83. doi: 10.1016/j.vaccine.2011.10.012. Epub 2011 Oct 18.

PMID:
22008822
12.

Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule.

Rodgers GL, Esposito S, Principi N, Gutierrez-Brito M, Diez-Domingo J, Pollard AJ, Snape MD, Martinón-Torres F, Gruber WC, Patterson S, Thompson A, Gurtman A, Paradiso P, Scott DA.

Vaccine. 2013 Oct 1;31(42):4765-74. doi: 10.1016/j.vaccine.2013.08.009. Epub 2013 Aug 16.

PMID:
23965217
13.

Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.

Diez-Domingo J, Gurtman A, Bernaola E, Gimenez-Sanchez F, Martinon-Torres F, Pineda-Solas V, Delgado A, Infante-Marquez P, Liang JZ, Giardina PC, Gruber WC, Emini EA, Scott DA.

Vaccine. 2013 Nov 4;31(46):5486-94. doi: 10.1016/j.vaccine.2013.06.049. Epub 2013 Sep 1.

PMID:
24004465
14.

13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial.

Silfverdal SA, Flodmark CE, Rombo L, Tansey SP, Sidhu M, Trammel J, Emini EA, Gruber WC, Scott DA, Gurtman A; 3012 study group.

Vaccine. 2013 Feb 18;31(9):1284-92. doi: 10.1016/j.vaccine.2012.12.066. Epub 2013 Jan 7.

PMID:
23306363
15.

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine.

Frenck R Jr, Thompson A, Yeh SH, London A, Sidhu MS, Patterson S, Gruber WC, Emini EA, Scott DA, Gurtman A; 3011 Study Group.

Pediatr Infect Dis J. 2011 Dec;30(12):1086-91. doi: 10.1097/INF.0b013e3182372c6a.

PMID:
21983216
16.

Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients.

Lin PL, Michaels MG, Green M, Mazariegos GV, Webber SA, Lawrence KS, Iurlano K, Greenberg DP.

Pediatrics. 2005 Jul;116(1):160-7.

PMID:
15995047
17.

Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13®].

Duggan ST.

Drugs. 2010 Oct 22;70(15):1973-86. doi: 10.2165/11205110-000000000-00000. Review.

PMID:
20883054
18.

Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.

Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N, Porat N, Gurtman A, Gruber WC, Scott DA.

Clin Infect Dis. 2013 Oct;57(7):952-62. doi: 10.1093/cid/cit428. Epub 2013 Jun 26.

19.
20.

Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes.

Grant LR, O'Brien SE, Burbidge P, Haston M, Zancolli M, Cowell L, Johnson M, Weatherholtz RC, Reid R, Santosham M, O'Brien KL, Goldblatt D.

PLoS One. 2013 Sep 23;8(9):e74906. doi: 10.1371/journal.pone.0074906. eCollection 2013.

Items per page

Supplemental Content

Write to the Help Desk